Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nefertari McClarity

Nurse Practitioner, Family Sugar Land, TX Nurse Practitioner

NPI 1386074888 CMS profile 10601458

19875 Southwest Fwy, Suite 100, Sugar Land, TX 77479

Open in the dashboard

General payments

$9,034

410 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nefertari McClarity of Sugar Land, TX is reported in the CMS Open Payments database as having received $9,034 across 410 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,710 109
2024 General $1,930 89
2023 General $1,742 76
2022 General $1,292 63
2021 General $1,360 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nefertari McClarity
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Nefertari McClarity were reported at $2,710. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Nefertari McClarity Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,360 $124 $35–$379 $132
2022 $1,292 $141 $44–$430 $149
2023 $1,742 $154 $49–$476 $160
2024 $1,930 $165 $51–$504 $164
2025 $2,710 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,183 43 payments
  2. AstraZeneca Pharmaceuticals LP $1,092 55 payments
  3. CSL Behring $881 37 payments
  4. GlaxoSmithKline, LLC. $860 49 payments
  5. Novartis Pharmaceuticals Corporation $600 30 payments
  6. Regeneron Healthcare Solutions, Inc. $526 22 payments
  7. BioCryst US Sales Co., LLC $510 27 payments
  8. Grifols USA, LLC $422 21 payments
  9. kaleo, Inc. $363 16 payments
  10. Amgen Inc. $337 16 payments
  11. Other $2,260 94 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,965 408 payments
  2. Education $59 1 payment
  3. Consulting Fee $10 1 payment
Products named General payments · program years 2021–2025
  1. CUVITRU $760 27 payments
  2. TRELEGY ELLIPTA $695 38 payments
  3. Hizentra $613 26 payments
  4. TEZSPIRE Respiratory $586 25 payments
  5. Orladeyo $476 26 payments
  6. Xembify $422 21 payments
  7. XOLAIR $369 17 payments
  8. DUPIXENT $357 16 payments
  9. TEZSPIRE Inflammation $319 15 payments
  10. TAKHZYRO $285 11 payments
  11. Other $4,572 208 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

210

Median for Nurse Practitioner: 389

Drug cost

$601,146

Median for Nurse Practitioner: $21,885

Branded share of claims

52.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orladeyo Berotralstat Hydrochloride Brand 14 $562,277
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $16,726
Breo Ellipta Fluticasone/Vilanterol Brand 27 $14,992
Epinephrine Generic 16 $3,473
Azelastine Hcl Generic 32 $991
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $749
Fluticasone Propionate Generic 19 $574
Ipratropium Bromide Generic 18 $451
Albuterol Sulfate Hfa Albuterol Sulfate Brand 16 $409
Montelukast Sodium Generic 15 $313

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XOLAIR
  • Novartis Pharmaceuticals Corporation $193
  • Genentech USA, Inc. $59
$252 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $135
  • Amgen Inc. $87
$222 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $141
  • GENZYME CORPORATION $32
$173 — —
Orladeyo
  • BioCryst US Sales Co., LLC $169
$169 14 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $137
$137 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

410 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record